William Blair Analysts Decrease Earnings Estimates for BRNS

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Equities researchers at William Blair decreased their FY2025 earnings estimates for Barinthus Biotherapeutics in a research report issued to clients and investors on Wednesday, May 7th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of ($1.63) for the year, down from their previous estimate of ($1.52). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.69) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.15).

Several other equities research analysts have also commented on the stock. Alliance Global Partners restated a “buy” rating on shares of Barinthus Biotherapeutics in a research note on Monday, March 24th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, March 21st.

Barinthus Biotherapeutics Trading Up 7.3%

Shares of NASDAQ:BRNS opened at $0.93 on Monday. The firm’s 50 day moving average is $0.89 and its two-hundred day moving average is $1.01. Barinthus Biotherapeutics has a 52 week low of $0.64 and a 52 week high of $2.44. The firm has a market capitalization of $37.52 million, a P/E ratio of -0.62 and a beta of -0.80.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. acquired a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest holding. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.